Global Peptide Therapeutics Market to be Fueled by Increasing Prevalence of Cancer and Diabetes

The global market for peptide therapeutics market derives much of its demand from the treatment of cancer and diabetes. The rising incidence of these diseases is making way for the advancement of peptide drugs, which in turn is propelling the global peptide therapeutics market. Additionally, the technical advancements in peptide drugs have resulted in a reduction in total production cost, fueling the production process of new peptide drugs.

Browse Full Global Peptide Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

On the other hand, API manufacturers are facing a tough challenge from the complex structure of peptides. Other than this, the lack of regulatory standards to arbitrate developments in peptide drugs is also hampering the growth of the peptide therapeutics market. However, biotech enterprises are identifying prospects for future growth in collaboration with major pharmaceutical firms across the globe.The global peptide therapeutics market is expected to expand at a CAGR of 2.8% during the period from 2014 to 2020 in order to reach US$23.7 billion by 2020. The market had reached a value of US$18.9 billion in 2013.

Market for Respiratory Disorders Poised to Grow at Highest CAGR between 2014 and 2020

Peptide therapeutics find application in the treatment of various kinds of ailments such as cardiovascular, nervous, gastrointestinal, respiratory, metabolism-related, in addition to cancer, various infections, and pain. The cancer market was the dominant application segment of the peptide therapeutics market in 2013. However, the respiratory disorder market segment is projected to develop at the highest CAGR during the period from 2014 to 2020 owing to the recent approval of lucinactant, sold under the brand name Surfaxin.

The global peptide therapeutics market is analyzed on three fronts: Route of administration, marketing status, and regional distribution of the global industry. Based on route of administration, parenteral and oral are the two segments of this market, while branded peptide therapeutics and generic peptide therapeutics are the segments of the global market on the basis of marketing status. The market for generic peptides is expected to do well in the next few years on account of patent expirations expected in the branded peptide market in the near future.

Asia Pacific to Report Highest Compound Annual Growth Rate from 2014 to 2020

Regionally, the global peptide therapeutics market is distributed among North America, Europe, Asia Pacific, and the Rest of the World, wherein the global market is dominated by the North American and European markets, which jointly occupy over 60% of the global market. However, in spite of the dominance of these regions in the global market, the peptide therapeutics market in Asia Pacific is poised to grow at the highest CAGR during the period from 2014 to 2020.The peptide therapeutics market in Asia Pacific is majorly driven by the rapid growth of this market in China, India, and Japan. The rise in economic stability and increased awareness pertaining to the treatment of various diseases are the major factors fueling the growth of the market in this region.

Browse Full Press Release Report: http://www.transparencymarketresearch.com/pressrelease/peptide-therapeutics-market.htm

Japan is the second largest market in the global individual pharmaceutical industry, whereas China and India have a huge population pool suffering from various diseases and ailments that are cured with the help of peptide therapeutics. These factors are expected to establish Asia Pacific as the most promising market for peptide therapeutics in the near future. China and India are also emerging as some of the largest peptide API suppliers in the world.

Amgen, Inc., Bachem Holding AG, AstraZeneca Plc, CordenPharma Int. GmbH, Ipsen S.A., Eli Lilly and Co., Lonza Group Ltd., Novartis AG, Merck & Co., Inc., Novo Nordisk A/S, Roche Holdings AG, PolyPeptide Group, Sanofi, Millennium Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are the major enterprises working in the global peptide therapeutics industry. The market is mostly concentrated as Takeda, Teva, and Novo Nordisk collectively hold more than 50% of the overall peptide therapeutics market.

The forthcoming patent expiry of Copaxone by Teva and Velcade by Millennium Pharma and the projected launch of their generic alternatives are expected to change the dynamics of the global peptide therapeutics market in the near future.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=418

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector — such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

LMWH is the Dominant Heparin Product Market in Europe and is Expected to Reach USD 3.14 Billion in 2022

Ultra low molecular weight heparin (ULMWHs) Market, low molecular weight heparin (LMWHs) Market, unfractionated heparin Market, anticoagulants Market.According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022”, the Europe heparin market was valued at USD 2,004.5 million in 2013 and is expected to grow at a CAGR of 5.2% from 2014 to 2022, to reach an estimated value of USD 3,148.0 million in 2022.

Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html

Heparin is a highly sulfated glycosaminoglycan sourced from animals, and used as an anticoagulant therapy in patients with blood clots and those undergoing surgery and dialysis. Heparin is generally available as an injection which need to be administered in presence of a healthcare practitioner. Its dosage depends on the medical condition of the patient, drug response and type of heparin. There are three types of heparin available in the European market namely unfractionated heparin, low molecular weight heparin (LMWH) and ultra-low molecular weight heparin (ULMWH). Low molecular weight heparin is the majorly used heparin type in Europe owing to its added advantage over unfractionated heparin. Low molecular weight heparins such as enoxaparin, dalteparin, tinzaparin and certoparin are the majorly sold heparin drugs in Europe.

europe-heparin-market

Unfractionated heparin is mainly used in hospitals and owing to its narrow therapeutic window and the possible risk of bleeding. Although, the effect of unfractionated heparin can be reversed using protamine sulphate, its use is diminishing owing to higher risk of osteopenia and thrombocytopenia. Therefore, researchers developed low molecular weight heparin which has lesser side effects and much safer compared to unfractionated heparin. Advent of low molecular weight heparin has decreased the market share of unfractionated heparin in Europe to less than 10% in 2013. Lovenox (enoxaparin) is a major brand in the LWMH market in Europe.

Further the advent of ultra-low molecular weight heparin in the European market has increased the market size of heparin products in this region. Arixtra (fondaparinux sodium) form GlaxoSmithKline plc is the major brand in Europe ULMWH market. Recently in 2012, Dr. Reddy’s Laboratory Ltd. had filed for marketing approval of its biosimilar version of Arxitra in Europe which was refiled in 2013 post receipt of comments for the European regulatory authorities. Entry of biosimilars will augment the market growth in Europe. However, concerns pertaining to the quality of heparin post the contamination issue in 2008 has alerted the regulatory authorities in Europe emphasizing on the traceability of raw heparin. This factor has delayed the market entry for biosimilar heparins in the European market. Presence of many LMWH product makes it the dominant product segment in the European heparin market. Moreover, LMWH will grow at a faster CAGR of 5.6% during the forecast period owing to it high demand and cost effective therapeutic performance compared to other heparins.

Browse the full Press Release : http://www.transparencymarketresearch.com/pressrelease/europe-heparin-market.htm

The Europe Heparin Market is segmented into the following categories:

Europe Heparin Market, by Product

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

Europe Heparin Market, by Country

United Kingdom

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

Germany

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

France

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

Spain

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

Italy

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

Rest of the Europe

Unfractionated Heparin

Low Molecular Weight Heparin (LMWHs)

Ultra-low Molecular Weight Heparin (ULMWHs)

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=4815

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Global Tuberculosis Testing Market Finds Encouragement in Growing Healthcare Efforts

The global tuberculosis testing market continues to grow as governments and institutions across the globe continue to make efforts to eradicate this deadly communicable disease. Statistics gathered by the WHO state that 9 million people acquired tuberculosis (TB) in 2013 and 1.5 met a fatal end, out of which 360,000 were HIV positive. These figures are declining with each passing year thanks to the increasingly effective diagnosis and treatment options offered to patients. It is estimated that such initiatives were able to save the lives of 37 million tuberculosis patients between 2000 and 2013.

Browse Full Global Tuberculosis Testing Market Report With Complete TOC @ http://www.transparencymarketresearch.com/tuberculosis-testing-market.html

Tuberculosis can be broken down into two types, namely active disease, which can transform to multi-drug resistant TB or MDR-TB, and latent disease. Tuberculosis also has a rare form called miliary TB, which occurs when TB infection finds its way to the bloodstream. The priority steps to counter MDR-TB are supreme quality of treatment for drug-susceptible TB to avert MDR-TB, expanding the reach of testing and detection of MDR-TB cases to remote regions, simplifying the access to good healthcare, infection control, and strengthening the political commitment, especially in BRIC nations, which constitute 50% of global TB cases.

Dedicated Efforts of Non-profit Organizations Drive Global Tuberculosis Testing Market

The efforts taken by governments, social activists, and several healthcare institutions have translated into positive results. A ripple effect of these efforts can also be seen in the growth of the global tuberculosis testing market. The global tuberculosis testing market was worth US$1,936.1 million in 2013. By 2020 this market is expected to reach a valuation of US$2,619.4 million, growing at a promising CAGR of 4.3% from 2014 to 2020.

The factors driving this gigantic growth are the rising number of tuberculosis cases, increasing acceptance of innovative methods for treating tuberculosis, and enhanced molecular and rapid culture diagnostic tests. The serious involvement and dedicated efforts of non-profit healthcare organizations are further boosting the global tuberculosis testing market. Growing tuberculosis cases have also resulted in increased research and development budgets, encouraging manufacturers to launch better testing technologies.

Serological Tests and IGRA Sub-segments to Grow the Fastest

The global tuberculosis testing market is classified on the basis of type and geography. The segments by product type are culture-based tests, smear microscopy, nucleic acid testing, radiography (chest x-ray), Mantoux test (tuberculin skin test), drug susceptibility test (DST), and other tests such as serological tests, ADA, and IGRA. Geographically, the global tuberculosis testing market is fragmented into North America, Asia Pacific, Europe, and Rest of the World.

Browse Full Press Release report http://www.transparencymarketresearch.com/pressrelease/tuberculosis-testing-market.htm

Out of these segments, culture-based tests hold a lion’s share in the global tuberculosis testing market. These tests are inclusive of both solid and liquid culture tests. Analysts predict that other segments such as serological tests and IGRA will grow rapidly in the coming five years as well. All of these tuberculosis testing methods generate quick results, offer improved accuracy, and require the patient to just one visit.

India and China to Make Steady Contribution to Growth of Global Tuberculosis Market

Geographically, Asia Pacific led the global tuberculosis testing market in 2013, closely followed by North America. The prime factor driving the unprecedented growth rate in Asia Pacific is a huge patient pool, which continues to grow at a rapid rate, especially in countries such as China and India. Though North America has a smaller patient pool, the tuberculosis testing market is expected to grow in this region due to increasing awareness, better healthcare infrastructure, and growing acceptance and adoption of expensive TB tests due to improving purchasing power of patients.

Some of the key players in the global tuberculosis testing market are Akonni Biosystems Inc., Abbott Laboratories, Becton, Alere Inc., Dickinson and Company, Cepheid, Epistem plc, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, QIAGEN, Hain Lifescience GmbH, Sanofi, and Thermo Fisher Scientific Inc.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2267

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Urgent Care Centers Market Flourishes as Patients Seek Basic Ambulatory Healthcare Solutions

The urgent care centers market is becoming an increasingly bigger part of the global health care system. It is a lucrative business model that is all about convenience for patients. As consumers look for less expensive healthcare options, urgent care centers and walk-in-clinics have been opening with greater frequency in various regions in recent years. Now-a-days, hospital systems also are increasingly expanding their networks into the urgent-care businesses by opening clinics at strategic locations in the world and buying out independent practices too. Moreover, the global urgent care centers market witnesses plenty of funding from private equity people who believe this is a gold rush for the forthcoming years.

Industry Insights into the Urgent Care Centers Market

Urgent care centers (UCCs) treat the most common illnesses and injuries – including cuts, back pain, colds, and ear infections. Such centers also take X-rays and perform simple urine, drug and blood tests on patients. However, UCCs do not provide critical care services and life-threatening surgeries. These centers are mainly considered as ambulatory healthcare centers such as convenient care clinics and emergency departments.

Browse Full Global Urgent Care Centers Market Report With Complete TOC @ http://www.transparencymarketresearch.com/urgent-care-centers-market.html

The urgent care center model is basically designed to provide cost-effective healthcare services and optimum quality to general public across the globe. Propelled by reduction in primary care appointments and frustration over long waits in hospitals and emergency rooms (for non-emergency care), the market has experienced a spurt of growth for urgent care facilities in the past few years. The number of medical facilities has increased from 8,000 to nearly 9,000 and consumers continue to yearn for similar immediate accessible medical care centers in many emerging regions of the world.

According to a market firm in the U.S. the UCCs market was valued at US$23.5 billion in 2013. Moderately growing at a CAGR of 3.8% from 2014 to 2020, the market is expected to reach US$30.5 billion by the end of 2020.

Such factors have been the driving force behind this monumental growth in the global urgent care centers market.

Services and Segmentations of UCC Market

The global urgent care centers market is broadly segmented on the basis of major services provided by medical centers. Some of the services listed in this market segment include, services for injury, trauma, illness, diagnostic, routine vaccination, physical, and screening and monitoring. Amongst them, the majority of the market share of revenue was generated by the illness services sector as of 2012. Most of the visits in the illness segment market in the same year were for conditions such as pharyngitis, urinary tract infections, upper respiratory tract infections, and fever and cold. The maximum number of illness related visits in 2012 was from the otitis media that accounted for more than 50%. However, the illness sector was followed by the injury segment in the global urgent care centers market. The UCCs market is widely fragmented with small and large players, wherein, the small players such as physician groups or physicians hold approximately 35% of the medical centers across various regions.

New Players will Find More Opportunities in Asia Pacific Region

Geographically, the global UCCs market is segmented into four major regions namely, Asia-Pacific, Europe, North America, and Rest of the World (RoW). North America once held the majority share of the overall UCCs market due to high adoption of UCCs for non-emergency conditions. This region is still expected to retain its position until the end of 2020.

Europe is at a distant second to this region in terms of growth and development regarding the walk-in health services and cost-effective medical care facilities. In the Asia-Pacific region, some of the major countries that offer high growth opportunities to existing and new companies in this market include India, China, Japan, New Zealand, and Australia.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2254

About Us

TMR is a U.S.-based market intelligence company driven by a global team of high-pedigree industry consultants, analysts, and researchers. TMR leverages its worldwide Syndicated Research, Custom Research, and Market Consulting expertise to help businesses make accurate decisions.

The company’s multi-disciplinary expertise has made it the preferred growth partner of hundreds of companies worldwide, from multibillion dollar conglomerates to emerging regional businesses. TMR’s exclusive blend of quantitative forecasting and trends analysis draws on proprietary data sources, tools, and techniques.

Contact

Mr.Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Asia Pacific Region to Dominate the Global FMD Vaccines Market

Transparency Market Research has released a new report on the global foot and mouth disease (FMD) vaccines market, which forecasts the growth of the overall FMD vaccines market at a CAGR of 8.8% during the period from 2014 to 2020. The FMD vaccines market was valued at US$0.51 billion in 2013. Due to the increasing frequency of FMD outbreaks, the report projects that the market will reach a worth of US$0.95 billion by the end of 2020. The report is titled ‘Foot and Mouth Disease Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020’.

Browse the full Foot and Mouth Disease Vaccines Market Report at http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

Caused by Aphthovirus, FMD is highly infectious viral disease which affects cloven-hoofed animals and leads to high mortality rate among the young stock such as lambs and piglets. The high prevalence of FMD across the globe affects the international trade in livestock products. The report provides an overview of the overall global FMD vaccines market and evaluates the growth drivers and restraints. Favorable government initiatives to control FMD outbreaks have boosted the growth of the global FMD vaccines market. Also, rising consumption of meat and dairy products demands healthy livestock, which has further fuelled the need for FMD vaccines. The report mentions that the involvement by various governments in purchasing FMD vaccines will lead to the dip in cost which will negatively affect the global FMD vaccines market in terms of revenue. FMD is caused by seven different types of serotype and the current vaccines are serotype-specific. Unpredictable serotype outbreaks can hamper the growth of the global FMD vaccines market. The report indicates that DNA vaccines will open new opportunities for the market during the forecast period.

Depending upon the type of vaccines, the report segments the global FMD vaccines market into conventional vaccines and emergency vaccines. The conventional vaccines have been further categorized into aluminum hydroxide or Saponin based vaccines, and oil-based vaccines. In 2013, oil-based FMD vaccines dominated the global FMD vaccines market with a market share of 63%, owing to its high efficiency and longer effect in treating the disease.

On the basis of application on the livestock, the global FMD vaccines market has been divided into cattle, pigs, sheep and goats, and others. To meet the increasing demand for milk and meat, cattle are reared the most across the globe, owing to which it has emerged as the largest application segment of the global FMD vaccines market. In Middle-east, as pork consumption is prohibited, the cattle segments contribute significantly to the FMD vaccines market of the region. The report predicts that the cattle segment will exhibit the fastest growth during the forecast horizon.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/foot-mouth-disease-vaccines.htm

Geographically, the global FMD vaccines market has been segmented into four key regions: Europe, North America, Asia Pacific, and Rest of the World. As the disease is non-existent in North America and Europe, the scope of the growth of the vaccines market in these regions is negligible. Due to frequent outbreaks of FMD in Asia Pacific region, the global FMD vaccines market has been dominated by this region with more than 70% share. The report documents the market revenue in China, India, Malaysia, South Korea, and rest of APAC during the forecast period. The report profiles some of the key vendors of the global FMD vaccines market such as Indian Immunologicals Ltd., Bayer AG, Agrovet Co., and Brilliant Bio Pharma Ltd.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2480

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Anxiety Disorders and Depression Treatment Market Expected to Reach USD 18.2 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020”, the global anxiety disorders and depression treatment market was valued at USD 22.5 billion in 2013 and is expected to reach USD 18.2 billion in 2020, at a CAGR of (1.25%) from 2014 to 2020.

Anxiety is a biological reaction to stress, trauma and fear, which can be experienced by anyone in their lifetime, whereas depression is a mental state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Depression affects 10% to 15% men and about 10% to 25% women. According to the World Health Organization (WHO), to date, over 350 million people have been affected by depression globally. The Anxiety and Depression Association of America revealed that at present approximately 40 million people in the U.S. are suffering from anxiety disorder and treating these patients costs around USD 42 billion each year. Thus, high prevalence of anxiety disorders and depression helped the market to transform itself into a billion dollar industry. However, the current scenario indicates that the overall anxiety disorders and depression treatment market would decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants.

Browse the full Anxiety Disorders and Depression Treatment Market Report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html

The anxiety disorders and depression treatment market has been segmented based on the drug classes commonly used for the treatment of various types of anxiety disorders and depression such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of over 30% of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue in the near future, reporting a CAGR of 14.2% from 2012 to 2016 and a CAGR of 4.3% from 2016 to 2020. Increasing influx of generic formulations as well as patent expiry of leading branded formulations such as Cymbalta, Lexapro and Effexor XR are some of the major factors that would negatively affect the growth of the segment. Moreover, with the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the anxiety disorders and depression treatment market. Hence, the future growth of the market would depend on commercialization of novel drugs for new indications.

Major pipeline drugs identified and expected to be launched during the forecast period from 2014 to 2020 include Brintellix [(Vortioxetine-Lu AA21004) (Lundbeck and Takeda)], Brexpiprazole [(OPC-34712) (Otsuka)] and ALKS-5461 [(FDC-buprenorphine and samidorphan) (Alkermes plc)]. The positive clinical trial outcomes of these drugs and anticipated commercialization during the forecast period are expected to fuel the growth of antidepressants and anxiolytic drugs market in the near future.

Geographically, North America accounted for the largest share of the anxiety disorders and depression treatment market in 2013 (over 35%). The U.S. accounted for the highest share of the revenue for each drug class due to the presence of one or more branded formulations that influenced the market dynamics significantly. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated due to the presence of cheap generic products and several antidepressant drugs available on prescription for the same indication. Hence, the region is expected to witness a negative CAGR throughout the forecast period from 2014 to 2020. Asia Pacific is estimated to witness an appreciable growth rate (0.02%) due to various factors such as positive marketing approval for novel medicines, growing geriatric population and presence of a large population base in the region. Additionally, strong economic growth in countries such as China, Japan, New Zealand and Australia would contribute to the growth of the market in Asia Pacific.

Browse the full Press Release :http://www.transparencymarketresearch.com/pressrelease/anxiety-disorders-depression-treatments.htm

The market displays intense competitive rivalry among existing players, as currently the market for antidepressant and anxiolytic drugs is highly fragmented comprising both large and small manufacturers. Major market players include AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, Inc., H. Lundbeck A/S, GlaxoSmithKline plc, Johnson & Johnson and Merck & Co., Inc. Eli Lilly and Company held the largest share of over 30% of the total anxiety disorders and depression treatment market in 2013. Product efficacy, differentiation, safety, well-developed distribution networks, and supply capabilities played a major role in determining the market position of the company.

The global anxiety disorders and depression treatment market has been segmented as follows:

Anxiety Disorders and Depression Treatment Market, by Drug Class

Selective Serotonin Reuptake Inhibitors (SSRIs)

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Atypical Antipsychotics

Tricyclic Antidepressants (TCAs)

Tetracyclic Antidepressants (TeCAs)

Monoamine Oxidase inhibitors (MAOIs)

Benzodiazepines

Beta-Blockers

Anticonvulsants

Anxiety Disorders and Depression Treatment Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1199

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr.Nachiiket

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Growing Global Geriatric Population to Drive Orthopedic Soft Tissue Market

The orthopedic soft tissue repair market is one of the prime components of the healthcare industry, and deals with injuries concerning the various types of connecting tissues in the body such as tendons, ligaments, and cartilage. It is responsible for the diagnosis, cure, as well as prevention – whenever possible – of soft tissue damage. These tissues are essential for a healthy function of the body’s structural and strength-imparting components such as bones and muscles. Virtually any natural action is a result of a collaborative effort between various bones and muscles, and a disorder or injury to the connecting link between bones and muscles leads to a reduction of the effective strength of the individual, regardless of the health of the bones or muscles themselves.

Browse Full Report Orthopedic Soft Tissue Market Research Report With Full TOC @ http://www.transparencymarketresearch.com/soft-tissue-repair-sports-medicine.html

This explains the link between the growing geriatric population all over the world and the orthopedic soft tissue repair market. With age, bones as well as connecting tissues weaken as a natural effect of the lifelong wear and tear. It also stiffens joints, the cumulative effect of which is an increased stress placed on the body’s structural components and more risk of damage. As a result, the increasing geriatric population worldwide is a major driver for the orthopedic soft tissue repair market. Sports injuries are the other major factor propelling the growth of the market. According to the Center for Disease Control and Prevention (CDC), around 2 million sports injuries occur in the U.S. every year, leading to about 30,000 hospitalizations.

ACL Reconstruction: Most Common Type of Soft Tissue Repair Procedure

The orthopedic soft tissue repair market is divided into categories according to type of surgery into the following segments:

Achilles tendinosis repair

Rotator cuff repair

Vaginal prolapse

Lateral epicondylitis

Gluteal tendon repair

Anterior cruciate ligament (ACL) reconstruction

Of these, the segment of ACL reconstruction holds the major share in the orthopedic soft tissue repair market. According to 2013 numbers, about 30% of soft tissue repair procedures were ACL reconstructions. The high cost of ACL treatment also contributes to the high share of the procedure, revenue-wise. The anterior cruciate ligament connects the femur, or thigh bone, to the tibia, or shin bone; it is situated almost exactly behind the knee cap. ACL injuries are common in sports, particularly ones that include a combination of heavy legwork and contact between players, such as soccer or rugby.

Rotator cuff surgeries are expected to become increasingly common, with the market for the procedure expected to rise at a moderate CAGR from 2014 to 2020. The rotator cuff is responsible for supporting the shoulder joint.

The U.S. to Maintain Top Position among Geographical Segments

Geographically, the orthopedic soft tissue repair market is divided into three categories, viz. the U.S., Europe, and Japan. Of these, the U.S. holds a dominant share in the market. The increasing standards and penetration of healthcare in the region, leading to a high geriatric population, and popularity of numerous sports, are considered to be the main causes behind the U.S.’s dominance. Increasing obesity in the U.S. is also considered to be a significant contributor to the U.S. orthopedic soft tissue repair market; obesity puts excessive load on joints and connecting tissues that aren’t strengthened sufficiently to deal with it. This, naturally, weakens the joints over time, leading to an increased risk of damage.

Preference for Minimally Invasive Surgeries to Drive Orthopedic Soft Tissue Repair Market

With growing innovation, more sophisticated and less intensive ways of performing soft tissue repair procedures are being formulated more frequently than ever. This fits in well with the general trend among patients of favoring minimally invasive surgeries. Research and development into these channels is an excellent opportunity emerging in the orthopedic soft tissue repair market.

The lack of such procedures at present means that many patients are opting for conservative treatment for soft tissue damage instead of surgeries. This is a major restraint to the market.

Major Players in the Orthopedic Soft Tissue Repair Market

The soft tissue repair market around the world is dominated by companies such as Arthrex, Inc., ArthroCare Corporation, Stryker Corporation, etc.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1768

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Growing Incidence of Congestive Heart Failure Drives Global Dilated Cardiomyopathy Therapeutics Market

Dilated cardiomyopathy is a condition strongly related to heart attacks, in which the ventricles are enlarged, resulting in a thinning of cardiac walls, and insufficient pumping of blood. Dilated cardiomyopathy can occur at any age, though it is most common in the 20-40 demographic. One of the major reasons of dilated cardiomyopathy is genetic. Some other factors that can cause dilated cardiomyopathy are thyroid disorders, viral infections of the heart, diabetes, alcoholism, and heart valve malformations.

Browse Full Global Dilated Cardiomyopathy Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Angiotensin II Receptor Blockers Held Largest Share of Dilated Cardiomyopathy Therapeutics Market in 2013 by Revenue

The dilated cardiomyopathy therapeutics market worldwide is segregated on the basis of drug class, pipeline drugs, and geography. The dilated cardiomyopathy therapeutics market globally in terms of drug class is broadly classified as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, aldosterone antagonists, and angiotensin II receptor blockers (ARBs). Of all the drug class, angiotensin II receptor blockers held the largest share of the dilated cardiomyopathy therapeutics market in 2013 by revenue, followed by beta blockers.

The high demand for the leading drugs for the treatment of dilated cardiomyopathy from developed regions such as Europe and North America is a reason for the large market shares of these classes of drugs. When used in combination either with ACE or ARBs, aldesterone antagonist drugs have proven to have a positive impact on the reduction of progressive conditions such as Duchenne muscular dystrophy (DMD).

The global dilated cardiomyopathy therapeutics market was worth US$651.0 million in 2013. By 2020, the global dilated cardiomyopathy therapeutics market is projected to be worth US$328.6 million which shows a decline of 7% CAGR from 2014 to 2020.

Clinical Trials May Halt Expected Reduction of Dilated Cardiomyopathy Therapeutics Market

The dilated cardiomyopathy therapeutics market worldwide is driven by growing incidence of congestive heart failure which is significantly related with DCM. On a global scenario, dilated cardiomyopathy is associated to 30% to 40% for congestive heart failure cases every year. Due to the growing incidence of congestive heart failure worldwide, several companies have initiated clinical trials for the advancement of therapeutics for dilated cardiomyopathy.

Some of the clinical trials undertaken are a phase II study by Array BioPharma in 2015 for its drug class ARRY-371797, a phase II study by Celladon Corporation in 2014 for its drug class MYDICAR. The dilated cardiomyopathy therapeutics market is expected to get a boost on the successful completion of these clinical trials. However, implantable devices such as heart pumps, pacemakers, and advancement in gene therapy will restrain the growth of dilated cardiomyopathy therapeutics market.

North America Leads Global Dilated Cardiomyopathy Therapeutics Market

According to geographical segmentation, the dilated cardiomyopathy therapeutics market is divided into four regions, which are Asia Pacific, Europe, North America, and Rest of the World (RoW). North America held the largest share of the dilated cardiomyopathy therapeutics market in 2013 owing to rising cases of heart diseases and acceptance for branded drugs.

The U.S. and Canada make up the dilated cardiomyopathy therapeutics market in North America. The prevalence of DCM in the U.S. is high; 5-8 people out of every 100,000 are diagnosed with DCM. In Canada, heart failure accounts for 9% of total deaths in the country, which is driving the dilated cardiomyopathy therapeutics market in North America.

In Europe, countries such as Spain, Germany, the U.K., and Italy contribute significantly towards the growth of the dilated cardiomyopathy therapeutics market. The dilated cardiomyopathy therapeutics market is growing in Asia Pacific and Rest of the World (RoW) owing to rising economic power, higher incomes, and growing demand for generic drugs.

Some of the key players in the dilated cardiomyopathy therapeutics market are Teva Pharmaceutical Industries Ltd , Merck & Co., Inc., Array BioPharma, Inc., Celladon Corporation, GlaxoSmithKline plc, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., AstraZeneca plc and Vericel Corporation.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2293

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Global Tuberculosis Testing Market Finds Encouragement in Growing Healthcare Efforts

The global tuberculosis testing market continues to grow as governments and institutions across the globe continue to make efforts to eradicate this deadly communicable disease. Statistics gathered by the WHO state that 9 million people acquired tuberculosis (TB) in 2013 and 1.5 met a fatal end, out of which 360,000 were HIV positive. These figures are declining with each passing year thanks to the increasingly effective diagnosis and treatment options offered to patients. It is estimated that such initiatives were able to save the lives of 37 million tuberculosis patients between 2000 and 2013.

Browse Full Global Tuberculosis Testing Market Report With Complete TOC @ http://www.transparencymarketresearch.com/tuberculosis-testing-market.html

Tuberculosis can be broken down into two types, namely active disease, which can transform to multi-drug resistant TB or MDR-TB, and latent disease. Tuberculosis also has a rare form called miliary TB, which occurs when TB infection finds its way to the bloodstream. The priority steps to counter MDR-TB are supreme quality of treatment for drug-susceptible TB to avert MDR-TB, expanding the reach of testing and detection of MDR-TB cases to remote regions, simplifying the access to good healthcare, infection control, and strengthening the political commitment, especially in BRIC nations, which constitute 50% of global TB cases.

Dedicated Efforts of Non-profit Organizations Drive Global Tuberculosis Testing Market

The efforts taken by governments, social activists, and several healthcare institutions have translated into positive results. A ripple effect of these efforts can also be seen in the growth of the global tuberculosis testing market. The global tuberculosis testing market was worth US$1,936.1 million in 2013. By 2020 this market is expected to reach a valuation of US$2,619.4 million, growing at a promising CAGR of 4.3% from 2014 to 2020.

The factors driving this gigantic growth are the rising number of tuberculosis cases, increasing acceptance of innovative methods for treating tuberculosis, and enhanced molecular and rapid culture diagnostic tests. The serious involvement and dedicated efforts of non-profit healthcare organizations are further boosting the global tuberculosis testing market. Growing tuberculosis cases have also resulted in increased research and development budgets, encouraging manufacturers to launch better testing technologies.

Serological Tests and IGRA Sub-segments to Grow the Fastest

The global tuberculosis testing market is classified on the basis of type and geography. The segments by product type are culture-based tests, smear microscopy, nucleic acid testing, radiography (chest x-ray), Mantoux test (tuberculin skin test), drug susceptibility test (DST), and other tests such as serological tests, ADA, and IGRA. Geographically, the global tuberculosis testing market is fragmented into North America, Asia Pacific, Europe, and Rest of the World.

Out of these segments, culture-based tests hold a lion’s share in the global tuberculosis testing market. These tests are inclusive of both solid and liquid culture tests. Analysts predict that other segments such as serological tests and IGRA will grow rapidly in the coming five years as well. All of these tuberculosis testing methods generate quick results, offer improved accuracy, and require the patient to just one visit.

India and China to Make Steady Contribution to Growth of Global Tuberculosis Market

Geographically, Asia Pacific led the global tuberculosis testing market in 2013, closely followed by North America. The prime factor driving the unprecedented growth rate in Asia Pacific is a huge patient pool, which continues to grow at a rapid rate, especially in countries such as China and India. Though North America has a smaller patient pool, the tuberculosis testing market is expected to grow in this region due to increasing awareness, better healthcare infrastructure, and growing acceptance and adoption of expensive TB tests due to improving purchasing power of patients.

Some of the key players in the global tuberculosis testing market are Akonni Biosystems Inc., Abbott Laboratories, Becton, Alere Inc., Dickinson and Company, Cepheid, Epistem plc, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, QIAGEN, Hain Lifescience GmbH, Sanofi, and Thermo Fisher Scientific Inc.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2267

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Increasing Incidences of Glioblastoma Multiforme Propels the Growth of Global Glioblastoma Treatment Market, Expected to Reach USD 0.91 Billion in 2022

According to a new market report published by Transparency Market Research “Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022,” the global glioblastoma treatment market was valued at USD 0.34 billion in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022.

Browse the full Pipeline Review of Glioblastoma Treatment Market Report at http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html

According to Columbia University Medical Center, GBM is the most malignant form of high-grade astrocytoma and is observed to be the most common adult primary brain tumor and make up approximately half of all astrocytomas. According to American Brain Tumor Association, there are two types of glioblastomas which are primary and secondary. Increasing incidence of glioblastoma multiforme is one of the prime factor driving the growth of the market globally. For instance, according to the U.S National Cancer Institute, in year 2015 22,850 cases are expected growing at 1.4% rate compared to 2014 and around 15,320 deaths growing at 2.6% compared to last year. GBM is considered as the most aggressive form of brain cancer which grows rapidly and develops glioma that represents overall 15.4% of all primary brain tumors and about 60% - 75% of all astrocytoma.

The global glioblastoma treatment market, by drugs was valued at USD 341.4 million in 2013 and is anticipated to reach USD 910.9 million by 2022, expanding at a CAGR of 11.4% from 2014 to 2022. Factors such as rising geriatric population, various organizations generating awareness coupled with introduction of novel therapies are driving the growth of this market. In addition, rising awareness against various types of brain tumors, development in drug delivery technologies and combination of modern diagnostic techniques are also supporting the growth of the market.

Temozolomide is the leading molecule in the GBM treatment market accounting for the largest market share in 2013. There are limited therapies available in the market for the treatment of GBM and most of them with overall patient’s survival rate from six to 14 months. Hence, the current pipeline of GBM therapeutics is strong and equipped with biologics, small molecules, devices, surgeries, and immunotherapy. In the current scenario, the pipeline review of glioblastoma seems to be strong as more than 50 molecules are in phase I and phase II clinical trials. The most promising drugs in phase III trials are Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These molecules have performed well in phase II of the clinical trials in terms of exceeding the overall survival rate.

Browse the full Press relaese Report :

http://www.transparencymarketresearch.com/pressrelease/global-glioblastoma-treatment-market.htm

North America and Europe dominated the global GBM market in 2013 majorly due to rising incidences of GBM in the regions coupled with technological advancements. According to World Health Organization (WHO), the incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the North America and Europe. GBM accounts for 12 to 15 % of all intracranial tumors and 50 to 60 % of astrocytic tumors. Thus, owing to the above mentioned factors the GBM market in North America and Europe is expected to retain its dominant position during the forecast period from 2014 – 2022. Asia Pacific is been estimated to be the most lucrative market for GBM due to increasing incidences of brain tumor in Asia Pacific countries such as China and others.

Merck & Co., Inc., F. Hoffmann-Le Roche AG, and Arbor Pharmaceuticals, LLC are the key players dominating the global GBM treatment market in 2013. Temodar (temozolomide) manufactured by Barr Pharmaceuticals, a subsidiary of Merck & Co. has dominated the global GBM treatment market in 2013 as it was the only available chemotherapy post radiation treatment. However, in 2012 the drug had lost its exclusivity thereby reducing the market share of the company in 2013 compared to the previous year. Teva Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, and others are the other players having presence in the global GBM market.

The pipeline review of glioblastoma treatment market has been segmented as below:

Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs

Bevacizumab (Avastin)

Temozolomide (Temodar and Temodal and Temcad)

Carmustine (BiCNU)

Global Glioblastoma Treatment Market Revenue and Forecast, by Geography

North America

Europe

Asia Pacific

Rest of the World

Global Pipeline Review of Glioblastoma Treatment

Overview

Late Stage (Phase III)

DCVax

Rindopepimut (CDX-110)

Others

Early Stage (Phase I, II and Pre clinical)

ABT-414

MM-398

ARC-100

AV0113

Cotara

Crenolanib

SGT-53

Endostatin

ANG1005

Others

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=4807

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com